Scott T. Tagawa, MD, MS

Scott T. Tagawa, MD, MS, professor of Medicine and Urology, and medical director of Genitourinary Oncology Research Program at Weill Cornell Medicine, discusses a phase I dose-escalation study of actinium-225 (225Ac-J591) in patients with progressive metastatic castration-resistant prostate cancer who had previously received at least 1 pathway inhibitor (NCT03276572).

The investigators of this trial did not reach a maximum tolerated dose, according to Tagawa. The study had 7 cohorts, and in 6 out of the 7, 1 patient had grade 4 anemia and thrombocytopenia. In the next cohort, none of the 6 patients had dose-limiting toxicities (DLTs), which were defined as grade 4 hematologic toxicity or grade 3/4 non-hematologic toxicity. Since none of these patients had DLTs, the study authors concluded that there was no maximum tolerated dose defined for this therapy. That cohorts received 93.3 KBq/kg which is now the recommended phase II dose.

Some adverse events that were not DLTs occurred with this therapy, such as grade 3 anemia in 1 patient and the rest were grade 1 and 2 toxicities.

<< View more resources and information regarding prostate cancer

Videos

Scott T. Tagawa, MD, MS, discusses a phase I dose-escalation study of actinium-225 in patients with progressive metastatic castration-resistant prostate cancer who had previously received at least 1 pathway inhibitor.

Results of Phase I Study Reach Primary End Point for mCRPC

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-PresbyterianWeill Cornell Medical Center, discusses fractionated dose 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC).

Investigators are currently evaluating 177Lu-PSMA-617 in a dose-escalation study to determine the highest tolerable dose of the drug in patients with progressive mCRPC. So far, the phase I trial has not shown any significant acute or dose-limiting toxicities, says Tagawa. The low-grade toxicities observed were dry mouth and nausea, which were seen in other the prospective phase II study from Australia.

Scott T. Tagawa, MD, MS, discusses fractionated dose 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer.

Expert Discusses Fractionated Dose 177Lu-PSMA-617 in mCRPC

Scott T. Tagawa, MD, MS, medical director, Genitourinary Oncology Research Program, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses the baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC).

Baseline  Analysis of CTC Enumeration and AR Localization in Men With mCRPC

Scott T. Tagawa, MD, MS, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses PSMA-targeting agents for the treatment of prostate cancer.

As resistance to AR-targeted therapy develops, PSMA expression will increase in many patients. An agent targeted against PSMA could be added in at this time.

PSMA-targeted therapy could also potentially be used in combination with AR-targeted therapy.

Both AR- and PSMA-targeted therapies are being investigated in clinical trials and are already making an impact.

Scott T. Tagawa, MD, MS | Authors

Articles

Results of Phase I Study Reach Primary End Point for mCRPC

Expert Discusses Fractionated Dose 177Lu-PSMA-617 in mCRPC

Baseline Analysis of CTC Enumeration and AR Localization in Men With mCRPC

Agents Targeted Against PSMA for Prostate Cancer